



ASX ANNOUNCEMENT

4 June 2025

CARDIEX SUCCESSFULLY COMPLETES INSTITUTIONAL PLACEMENT

Not for release to US wire services or distribution in the United States

Further to an ASX announcement on 30 May 2025, Cardiex Limited (ASX: CDX) (the **Company**), is pleased to announce the completion of a placement of 60,909,580 fully paid ordinary shares in the Company to institutional and sophisticated investors (the **Placement**) to raise \$2.4 million (before costs). New shares issued under the Placement will be issued at an offer price of \$0.04 per share (**Placement Shares**).

The Placement was well supported by existing institutional shareholders as well as a range of new and existing sophisticated investors. C2 Ventures Pty Limited (**C2V**), the Company's largest shareholder (and a company owned by directors Craig Cooper and Niall Cairns) will also participate in the Placement to subscribe for \$736,383.20 worth of Placement Shares. The issue of the Placement Shares to C2V is subject to shareholder approval at the Company's next general meeting, expected to be held in late July.

Funds raised from the Placement will largely be used for new device manufacturing, marketing and sales activities, and for commercial expansion, including scaling up supply chain operations relating to the CONNEQT Pulse device. Placement Shares will be issued utilising Cardiex's existing capacity under ASX Listing Rule 7.1 and will rank equally with existing ordinary shares from the date of issue.

42,500,000 Placement Shares will be issued under the Company's Listing Rule 7.1 placement capacity on 5 June 2025, and 18,409,580 Placement Shares will be issued to C2V subject to shareholder approval at the Company's next general meeting and therefore will not be issued under the Company's available placement capacity.

Blackpeak Capital Pty Ltd, Stralis Capital Partners Limited and Taylor Collison Limited acted as Joint Lead Managers to the Placement (**Joint Lead Managers**). The Joint Lead Managers will be paid a fee comprising:

- (a) a management fee of 4.00% of the Placement proceeds; and
- (b) a selling fee of 2.00% of the Placement proceeds,

except that (b) excludes Placement proceeds resulting from the participation of C2V and any directors of the Company (if applicable).

Approved by the Board of Directors and Released by the Company Secretary

- ENDS -

For more information, please contact:

Investor Relations

Rod Hinchcliffe

rod.hinchcliffe@mcpartners.com.au

Media Relations

Melissa Hamilton

melissa.hamilton@mcpartners.com.au

About Cardiex

Cardiex's mission is to increase longevity through medical technology advancements in vascular health. The Company's suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders - all based on the Company's market leading SphygmoCor® vascular biomarker technology. Cardiex is listed on the Australian Stock Exchange ("ASX:CDX").